BSc (Hons), PhD
PCUK Career Acceleration Fellow
My research focuses on improving radionuclide therapy for treatment of prostate cancer. While targeted radionuclide treatments such as 177Lu-PSMA are promising new treatments for men with metastatic prostate cancer, we cannot yet promise they will work despite sufficient tumour uptake.
I am investigating why these treatments may not work to their full potential by investigating the underlying radiobiological response to radionuclide therapy in models of prostate cancer. My research uses both drug combination screens and preclinical imaging to probe this underlying radiobiology to identify new hybrid imaging and chemo-radionuclide treatment strategies to overcome treatment resistance in the clinic.
Chan CY. et al, (2023), J Nucl Med
O'Neill E. et al, (2023), Theranostics, 13, 1302 - 1310